This story reports on results from a preliminary study for a device in development to treat atrial fibrillation. Although it appears to be intended as a business story, we think shareholders would care about cost and comparisons with existing alternatives as much as patients and consumers should care about these.
Since the story acknowledged that a competing device was already on the market, it wouldn’t have required much more work to do some comparative analysis – especially if our call for an independent expert’s perspective was heeded.
There was no discussion of costs.
The story did provide insight about the difference in heart attack, stroke and death in the groups taking medication alone or those who had received treatment with this device. However, since the story did note that there is currently a device on the market, it would have been helpful to readers to provide information about treatment with the other device affects the rate at which these things occur. A comparison of effectiveness would provide insight as to the relative merit for this new device.
The story did mention several of the harms associated with the use of this device along with the incidence with which they were observed.
There was adequate discussion of the evidence and that the main limitation of this study was its small size.
There was no overt disease-mongering of atrial fibrillation.
There were no independent sources interviewed to discuss the potential of this device to affect outcomes and patient care. This is a problem.
While mentioning that Johnson and Johnson had an ablation device approved for use in the treatment of atrial fibrillation, there was no discussion about how the results obtained with the Medtronic device compared.
Towards the end, the story mentions that the treatment device discussed is not yet approved for use, though a device made by a different company (Johnson and Johnson) has been used to treat AF for years.
Towards the end of the story, there was a clear statement that there is another device on the market that has been used for a long time in the treatment of atrial fibrillation.
We can’t be sure of the extent to which this story was influenced by a new release, so we judge this criterion Not Applicable.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like